---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013272"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:39:44.439315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports positive Phase 1a data for ABI-4334; to partner core inhibitor portfolio, focus on ABI-5366

## Summary
- ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.
- Phase 1a safety: mild-to-moderate AEs, no pattern, no clinically significant ECG abnormalities.
- Company will partner core inhibitor portfolio; no further internal clinical development for HBV cure.
- Prioritizing ABI-5366 (genital herpes) with Phase 1 expected H1 2024; second candidate by end of 2024.
- Cash runway extended into Q3 2024 due to reprioritization.

## SEC filing metadata
- accession: 0000950170-23-013272
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/0000950170-23-013272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023013272/asmb-20230418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013272
- JSON: https://secwatch.observer/filing/0000950170-23-013272.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.